AlphAIAlphAI — Financial news for AI agents
investing.comOCT 292 min read$BHC

Jefferies raises Bausch Health stock price target on revenue beat

Jefferies raised its price target for Bausch Health (BHC) to $8.00 from $6.50, maintaining a Hold rating. BHC reported Q3 2026 revenue of $2.94B, up 10% YoY, beating estimates. EBITDA was $1.31B, exceeding forecasts. The company raised its full-year 2026 guidance. BHC's stock trades at $8.85, above the new target and its 52-week high.

Original reporting
investing.com
Published Oct 29, 2026, 7:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 7:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$BHC
Bullish
high confidence
Mentioned
$BHC
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$BHCBullishMed
01

Why it matters

Earnings beat and guidance lift may attract short‑term buying, but the stock's price above the new target limits upside.

02

Market read

The earnings surprise and analyst upgrade provide a modest trading catalyst for BHC and may influence peer stocks in the sector.

03

What to watch

Potential headwinds from regulatory scrutiny of its drug portfolio and foreign exchange exposure.

Relevance 7/10Novelty 7/10Timing: post‑earnings today

Background

Bausch Health reported its 14th consecutive quarter of revenue and EBITDA growth, beating consensus estimates and prompting an analyst price‑target raise.

Company-level read

Ticker impact

$BHCBullishHigh confidence
Context

Jefferies raised its price target on Bausch Health to $8.00 after the company reported Q3 2026 revenue of $2.94 bn beating estimates and lifted full‑year guidance.

Expected impact

modest upward pressure as investors weigh the earnings beat against the already elevated price.

Evidence & confidence

Earnings beat and higher guidance typically support price gains, but the current price exceeds the new target, capping upside potential.

Market effects

Sector

Positive earnings surprise may lift the broader healthcare/pharmaceutical sector.

Regional

U.S. market participants may adjust exposure to specialty pharma stocks.

Global

Limited; impact confined to investors tracking U.S. listed health‑care equities.

Counterpoint

What could challenge this read

The stock is already above the new target, suggesting the rally may be exhausted and a pullback possible.

Key entities

  • company
    Bausch Health Companies

    U.S.-listed specialty pharmaceutical company (NYSE:BHC).

  • analyst
    Jefferies

    Equity research firm that raised the price target.

Read at source← All news

StoryBausch Health posts Q3 2026 earnings beat, raises full‑year guidance and launches $50 M buyback

Also covered by

4 outlets

Related articles

OCT 29
$BHCMedAI 8/10

Bausch Health Soars 21% on Beat-and-Raise Quarter: Core EBITDA Hits a “First Time” Milestone

Bausch Health (BHC) rose 21% after reporting adjusted EPS of $1.77, beating estimates, and raising its full-year outlook. Core EBITDA, excluding Bausch + Lomb, exceeded $1 billion for the first time. Xifaxan's growth and debt reduction contributed to the results. The company also anticipates a Medicare price impact on Xifaxan in 2027. AbbVie (ABBV) and Teva (TEVA) face similar challenges with their drugs. BHC's forward P/E remains below its five-year average.

finance.yahoo.com5 min
OCT 29
$BHCHighAI 8/10

Bausch Health Companies Inc (BHC) Q3 2026 Earnings Call Highlights: Adjusted EBITDA Tops

Bausch Health (BHC) reported Q3 2026 earnings, raising full-year guidance. Adjusted EBITDA exceeded $1B. CFO JJ Sharon noted a $100M+ impact from Xifaxan price adjustments. CEO Thomas Appio discussed Solta's growth and regulatory timelines. Salix revenue rose 16% to $831M, driven by Xifaxan. The company reduced debt by $521M and announced a $50M share repurchase program.

finance.yahoo.com2 min
OCT 29
$BHCHighAI 8/10

Bausch Health (BHC) Q3 2026 Earnings Call Transcript

Bausch Health (BHC) reported Q3 2026 earnings, marking 4 consecutive quarters of year-over-year revenue and adjusted EBITDA growth. The company exceeded $1 billion in quarterly adjusted EBITDA and reduced net debt by over $500 million. Salix revenue increased 16%, while international business grew mid-single-digit. The company raised its full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted cash flow from operations.

finance.yahoo.com2 min